Frontiers in Human Neuroscience
November 7, 2016
Elisabeth Haug, Merete G Øie, Ole A. Andreassen et al.
Background: Anomalous self-experiences (ASEs) aggregate in schizophrenia spectrum disorders, but the relationship between ASEs, and depression has been studied to a limited extent. Lower self-esteem has been shown to be associated with depression in early psychosis. Our hypothesis is that ASEs in early phases of schizophrenia are linked to lower levels of self-esteem, which in turn is...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
November 3, 2016
Kristian Gaarn Du Jardin, Heidi Kaastrup Müller, Betina Elfving et al.
A single i.v. infusion of ketamine, classified as an N-methyl-d-aspartate (NMDA) receptor antagonist, may alleviate depressive symptoms within hours of administration in treatment resistant depressed patients, and the antidepressant effect may last for several weeks. These unique therapeutic properties have prompted researchers to explore the mechanisms mediating the antidepressant effects of...
Forensic Science International
November 2016
Percy Bondallaz, Bernard Favrat, Haïthem Chtioui et al.
Traffic policies show growing concerns about driving under the influence of cannabis, since cannabinoids are one of the most frequently encountered psychoactive substances in the blood of drivers who are drug-impaired and/or involved in accidents, and in the context of a legalization of medical marijuana and of recreational use. The neurobiological mechanisms underlying the effects of cannabis...
Human Brain Mapping
November 1, 2016
Anna Abraham
The astounding capacity for the human imagination to be engaged across a wide range of contexts is limitless and fundamental to our day-to-day experiences. Although processes of imagination are central to human psychological function, they rarely occupy center stage in academic discourse or empirical study within psychological and neuroscientific realms. The aim of this paper is to tackle this...
Psychoneuroendocrinology
November 2016
Suzannah F. Isgett, Sara B Algoe, Aaron J. Boulton et al.
Ample research suggests that social connection reliably generates positive emotions. Oxytocin, a neuropeptide implicated in social cognition and behavior, is one biological mechanism that may influence an individual's capacity to extract positive emotions from social contexts. Because variation in certain genes may indicate underlying neurobiological differences, we tested whether several SNPs...
Pharmacological Research
November 2016
Danilo de Gregorio, Luca Posa, Rafael Ochoa-Sanchez et al.
d-lysergic diethylamide (LSD) is a hallucinogenic drug that interacts with the serotonin (5-HT) system binding to 5-HT1 and 5-HT2 receptors. Little is known about its potential interactions with the dopamine (DA) neurons of the ventral tegmental area (VTA). Using in-vivo electrophysiology in male adult rats, we evaluated the effects of cumulative doses of LSD on VTA DA neuronal activity,...
Journal of Maharishi Vedic Research Institute
November 1, 2016
David W. Orme-Johnson
Maharishi Mahesh Yogi has proposed a fundamentally new theory of society, which posits a field of collective consciousness as the causal level of social organization underlying all patterns of relationships between and among individuals and social groups. The purpose of the present study was to use factor analysis to examine the inter-correlation patterns among the dependent variables used in...
Neurotoxicity Research
November 1, 2016
Patrycja Kleczkowska, Irena Smaga, Malgorzata Filip et al.
Cannabinoids are still classified as illegal psychoactive drugs despite their broad and increasingly acknowledged therapeutic potential. These substances are most famous for their wide recreational use, particularly among young adults to either alter the state of consciousness, intensify pleasure induced by other psychoactive substances or as an alternative to the previously abused drugs. It is...
Clinical Pharmacology in Drug Development
November 1, 2016
Paul Glue, Gavin Cape, Donna Tunnicliff et al.
66 citations
Ibogaine is a psychoactive substance that may reduce opioid withdrawal symptoms. This was the first clinical trial of noribogaine, ibogaine's active metabolite, in patients established on methadone opioid substitution therapy (OST). In this randomized, double-blind, placebo-controlled single ascending-dose study, we evaluated the safety, tolerability, and pharmacokinetics of noribogaine in 27...
Therapeutic Advances in Psychopharmacology
October 27, 2016
Ananya Mahapatra, Rishi Gupta
37 citations
Psilocybin is a naturally occurring alkaloid, pharmacologically similar to the classic hallucinogen lysergic acid diethylamide (LSD). Although primarily used as a recreational drug or an entheogen in particular cultural settings, recent population based studies have shown that it does not lead to serious physical or mental health problems or dependent use. In view of recent work demonstrating...